Cancer Incidence in People With Intellectual Disability and Down Syndrome in Australia: A Cohort Study
Cancer Medicine · 2026
DOI: 10.1002/cam4.71866 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Julian Trofimovs und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Centre of Excellence in Intellectual Disability Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Down Syndrome, Intellectual Disability, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Aspen Medical Foundation.
Abstract (Originalsprache)
Objective
There is inconsistent data on cancer risk in people with intellectual disability. Our primary objective was to compare the incidence of cancer in people with and without intellectual disability. Methods and Analysis A cohort study using linked population‐based administrative and cancer registry data in New South Wales, Australia 2001–2018. We compared the incidence of cancer in people with intellectual disability and a comparator group without intellectual disability matched for age, sex and residential postcode. We also compared cancer incidence in people with Down syndrome and people with intellectual disability without Down syndrome. We used a flexible parametric survival model accounting for competing risks.
Results
People with intellectual disability had a slightly higher risk of developing any cancer (sub‐hazard ratio, SHR 1.07 [95% CI 1.03 to 1.12]) compared to those without intellectual disability. An increased risk was evident in the 0–14 year (SHR 2.19, 95% CI 1.85 to 2.59) and 15–49 year (SHR 1.34, 95% CI 1.23 to 1.46) age groups, and a decreased risk was observed for those aged 50 years and above (SHR 0.93, 95% CI 0.88 to 0.98). People with intellectual disability had a higher risk of colorectal cancer (SHR 1.32, 95% CI 1.15 to 1.51) and a lower risk of prostate cancer (SHR 0.45, 95% CI 0.38 to 0.53) and melanoma (SHR 0.75, 95% CI 0.64 to 0.88). People with Down syndrome had a significantly higher risk of childhood cancer (SHR 7.94, 95% CI 5.72 to 11.04) compared to those with other intellectual disability, and a similar risk as an adult.
Conclusions
These findings underscore the need for targeted health promotion campaigns and, for adults, customised cancer screening programmes to improve access, acceptability and outcomes for people with intellectual disability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Centre of Excellence in Intellectual Disability Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
- The Kirby Institute, University of New South Wales, Sydney, Australia.
- Centre for Big Data Research in Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
- School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
ORCID-Profile: Julian Trofimovs, Preeyaporn Srasuebkul, Sallie-Anne Pearson, Julian N Trollor
Förderung
- National Health and Medical Research Council
- Aspen Medical Foundation
Zitieren
APA
Trofimovs, J., Vajdic, C. M., Srasuebkul, P., Pearson, S. A., & Trollor, J. N. (2026). Cancer Incidence in People With Intellectual Disability and Down Syndrome in Australia: A Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.71866
Vancouver
Trofimovs J, Vajdic CM, Srasuebkul P, Pearson SA, Trollor JN. Cancer Incidence in People With Intellectual Disability and Down Syndrome in Australia: A Cohort Study. Cancer Medicine. 2026. doi:10.1002/cam4.71866
BibTeX
@article{Trofimovs2026,
author = {Trofimovs, Julian and Vajdic, Claire M and Srasuebkul, Preeyaporn and Pearson, Sallie-Anne and Trollor, Julian N},
title = {Cancer Incidence in People With Intellectual Disability and Down Syndrome in Australia: A Cohort Study},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71866}
}
EUVIMED